

Oncology Today with Dr Neil Love: An interview with Matthew R Smith, MD, PhD
— Management of Prostate Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following adverse events of special interest is linked with long-term androgen deprivation therapy (ADT) use for prostate cancer?
 - a. Hyperphosphatemia
 - b. Diabetes**
 - c. Interstitial lung disease
 - d. Trismus

2. The use of radium-223 for the treatment of prostate cancer aims to disrupt metastatic activity in which tissue type?
 - a. Liver
 - b. Bone**
 - c. Lung
 - d. Brain
 - e. All of the above

3. The Phase II BRCAAway study evaluated the efficacy of abiraterone and which of the following agents both as a monotherapy and in combination for metastatic castration-resistant prostate cancer with a homologous recombination repair mutation?
 - a. Leuprolide
 - b. Rucaparib
 - c. Niraparib
 - d. Olaparib**

4. The Phase III ARASENS trial evaluated the addition of which agent to ADT and docetaxel for patients with metastatic hormone-sensitive prostate cancer?
 - a. Enzalutamide
 - b. Apalutamide
 - c. Darolutamide**
 - d. Abiraterone

5. Which of the following side effects is more commonly associated with enzalutamide than darolutamide?
 - a. Hair and nail loss
 - b. Rash
 - c. Nausea
 - d. Gynecomastia**